Department of Preventive Medical Sciences, Fujita Health University School of Medical Sciences.
Department of Hygiene.
J Hypertens. 2021 Jan;39(1):84-89. doi: 10.1097/HJH.0000000000002606.
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and play essential roles in the pathogenesis of cardiovascular disease. Previous cross-sectional studies showed that the levels of several circulating miRNA are associated with hypertension, but there are no prospective longitudinal studies using a general population. The aim of this study is to evaluate the impact of circulating vascular-related miRNA (miR-126, miR-221, and miR-222) on changes in blood pressure and new-onset hypertension in a Japanese population.
We conducted a 5-year longitudinal study using 192 health examination participants (87 men and 105 women). Serum miRNAs were measured using quantitative reverse transcription-PCR. Information regarding lifestyle and health condition was obtained using a self-administered questionnaire. Logistic regression analyses were performed to calculate odds ratios and 95% confidence intervals for new-onset hypertension in the 5-year period between the low and high group of serum miRNAs.
Serum levels of miR-126, miR-221, and miR-222 were significantly and negatively associated with changes in SBP and the rate of change of SBP. Serum miR-126, miR-221, and miR-222 levels were significantly lower in new-onset hypertensive patients compared with normotensive individuals. The confounding factors adjusted odds ratios of each 1 increment in serum miR-126, miR-221, and miR-222 levels were 0.82 (95% confidence interval: 0.69-0.98), 0.79 (0.68-0.91), and 0.61 (0.46-0.81) for new-onset hypertension, respectively.
Low serum levels of miR-126, miR-221, and miR-222 were associated with increased blood pressure and new-onset of hypertension. These circulating miRNAs are potential candidate biomarkers for the prediction of hypertension.
微小 RNA(miRNA)是一种小的非编码 RNA,可调节基因表达,在心血管疾病的发病机制中发挥重要作用。先前的横断面研究表明,几种循环 miRNA 的水平与高血压有关,但尚无使用一般人群的前瞻性纵向研究。本研究旨在评估循环血管相关 miRNA(miR-126、miR-221 和 miR-222)对日本人群血压变化和新发高血压的影响。
我们进行了一项为期 5 年的纵向研究,共纳入 192 名健康体检参与者(87 名男性和 105 名女性)。使用定量逆转录-PCR 测定血清 miRNA。使用自我管理问卷获取有关生活方式和健康状况的信息。在 5 年内进行逻辑回归分析,以计算低和高血清 miRNA 组新发高血压的比值比和 95%置信区间。
血清 miR-126、miR-221 和 miR-222 水平与 SBP 的变化和 SBP 变化率呈显著负相关。与正常血压者相比,新发高血压患者的血清 miR-126、miR-221 和 miR-222 水平显著降低。调整混杂因素后,血清 miR-126、miR-221 和 miR-222 水平每增加 1 个单位,新发高血压的比值比分别为 0.82(95%置信区间:0.69-0.98)、0.79(0.68-0.91)和 0.61(0.46-0.81)。
血清 miR-126、miR-221 和 miR-222 水平较低与血压升高和新发高血压相关。这些循环 miRNA 可能是预测高血压的潜在候选生物标志物。